Yi-long Wu
Yi-long Wu
Professor of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
Verified email at
Cited by
Cited by
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma
TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ...
New England Journal of Medicine 361 (10), 947-957, 2009
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ...
The lancet oncology 12 (8), 735-742, 2011
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer
P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ...
Journal of Thoracic Oncology 11 (1), 39-51, 2016
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ...
New England Journal of Medicine 376 (7), 629-640, 2017
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The lancet 393 (10183), 1819-1830, 2019
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open …
YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ...
The lancet oncology 15 (2), 213-222, 2014
Lung cancer: current therapies and new targeted treatments
FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran, YL Wu, ...
The Lancet 389 (10066), 299-311, 2017
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, ...
The Lancet 374 (9699), 1432-1440, 2009
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert, P Sunpaweravong, SS Leong, ...
Journal of clinical oncology 29 (21), 2866-2874, 2011
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ...
The Lancet 372 (9652), 1809-1818, 2008
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised …
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ...
Cancer cell 17 (1), 77-88, 2010
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, F Tsuji, R Linke, ...
The Lancet Oncology 18 (11), 1454-1466, 2017
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open …
YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu, Y Cheng, B Han, ...
Annals of oncology 26 (9), 1883-1889, 2015
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu, HY Tu, HJ Chen, ...
Clinical cancer research 23 (12), 3012-3024, 2017
The system can't perform the operation now. Try again later.
Articles 1–20